The above findings confirm that the TIGIT-blocking monoclonal antibody can significantly enhance the function and anti-tumor effect of NK in the MM tumor microenvironment compared to EZH2 inhibition alone or TIGIT blockade in the presence of EZH2 inhibition. This evidence concerns the gene TIGIT and Miyoshi myopathy.